Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 3rd International Conference on Pharmaceutical Research
&
Innovations in Pharma Industry Barcelona, Spain.

Submit your Abstract
or e-mail to

pharmaresearch@eventsupporting.org
pharmaresearch@eventsupporting.org

Scientific Program Day 1
Scientific Program Day 2

Day :

  • Pharmaceutical Research and Development | Pharmaceutical Industry | Active Pharmaceutical Ingredients | Formulations and NNDS | Drug discovery and NCEs | Good Manufacturing Practices (GMP) | Regulatory Affairs | Pharmaceutical Manufacturing, Scale Up and Tech transfer
Location: Barcelona, Spain
Speaker

Chair

Rashid Mahmood

Surge Laboratories Private Limited, Pakistan

Session Introduction

Dipak Chetia

Dibrugarh University, India

Title: Antimalarial drug discovery and development: Issues and prospects

Time : 13:50-14:20

Speaker
Biography:

There was no signifi cant progress in the reduc on of malaria cases globally during the period 2015-2017 as per the latest epidemiological report (WHO, Malaria Report 2018). The malaria aff ected countries mainly rely on Artemisinin-based Combina on Therapy (ACT) as no new drug has been discovered during the last couple of years. Therefore, the discovery of new an malarial drugs to target the parasite at various stages of its life cycle is an urgent necessity to address the current stagnant therapeu c situa on as well as to fi ght against the rapidly emerging resistant strains of the malaria parasites. The objec ve of the presenta on is to highlight the achievements and shortcomings, possibili es of working on new areas for development of potent an malarial drugs, problems and issues in the screening of an malarial compounds, necessity for development of easy, aff ordable and fast screening method.

Salient points related to current status and possible newer research targets to be taken into considera on for an malarial drug discovery and development shall be systema cally discussed and deliberated (Figure 1). The prime target of currently used an malarial drugs is the erythrocy c stage of the parasite and except few, others show very less therapeu c effi  cacy individually. Addi onally, most of these drugs are not eff ec ve against resistant malaria. Potent an malarial drug candidates based on novel targets need to be developed not only for erythrocy c stage but also to target the parasite at other stages which may work by diff erent mechanism of ac on against the parasites. There is a need for developing easier, aff ordable and fast screening method to enable more medicinal chemists to involve in the new an malarial drug discovery and development programmes. The development of most eff ec ve and long ac ng chemicals/ drugs for malaria interven on is equally important in the control of malaria.

Abstract:

Dipak Che a is a Professor of Pharmaceu cal Chemistry of the Department of Pharmaceu cal Sciences, Dibrugarh University, Assam, India. He is involved in the discovery, design and development of an malarial drugs of synthe c and natural origin since last few years. Currently, he is also serving addi onally as the Dean, Research and Development of Dibrugarh University. He is the Co-ordinator of the UGC-SAP programme awarded to the Department of Pharmaceu cal Sciences, Dibrugarh University for An malarial Drug Discovery and Development. He has published 67 research papers and 14 research scholars have completed PhD degree under him. His current research interest is drug discovery against resistant malaria.